AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

(Reuters) - AbbVie Inc on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc .Shares of the Illinois-based drugmaker rose more than 3% to $82.10. AbbVie is counting on the Allergan acquisition, expected to close early next year, to help lessen its dependence on Humira, the world's top selling medicine, and diversify its product..